Attenuation of Cardiac Effects of Arteriovenous Fistula Creation With Losartan

• Status: Completed
• Trial end date: 2014-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective is to determine if the use of losartan, an angiotensin II receptor blocker, can attenuate left ventricular hypertrophy, independent of its antihypertensive effects, in patients with near end stage chronic kidney disease (CKD) who have an arteriovenous fistula created.

Secondary outcomes include the impact of the medication on BNP and hyperkalaemia

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Melbourne Health
• Treatments: Losartan

Criteria

Inclusion Criteria:

1. Diagnosis of CKD at near-end stage renal failure (CKD Stage IV) ( eGFR = 15-30 mls/min).

2. Age >18 years of age and <85 years of age.

3. Males and post-menopausal, sterile women. Non-pregnant pre-menopausal women should be on adequate contraception and have no intention of becoming pregnant during the duration of the study.

4. At baseline TTE LVEF>45%

5. Willing and able to give informed consent.

Exclusion Criteria:

1. Serum potassium level of more than 5.5 mmol/L

2. Acute myocardial infarction or cerebrovascular accident in the previous 6 months.

3. Severe uncontrolled hypertension (diastolic BP >100mmHg or systolic BP >160 mmHg)

4. Evidence or suspicion of renovascular disease.

5. Atrial fibrillation

6. Evidence or suspicion of collagen disease, cancer, psychiatric disorder that interferes with patient compliance, drug or alcohol abuse, pregnancy, breast feeding and ineffective contraception.